# 參考文獻追蹤表（內部工作用）

> **說明**：此檔為內部追蹤用，記錄各文獻的引用位置與確認狀態。
> **正式版**：`docs/00_thesis/chapters/06_參考文獻.md`（APA 格式）
> **下載索引**：`docs/02_literature/Reference_Download_Index.md`
> **最後更新**：2026-02-09

---

## 全論文引用清單

### 診斷標準與指引

| # | 引用 | 縮寫 | 用於 |
|---|------|------|------|
| 1 | James, P. A., et al. (2014). 2014 evidence-based guideline for the management of high blood pressure in adults (JNC 8). *JAMA*, 311(5), 507-520. | JNC 8 | Ch2 高血壓診斷標準 |
| 2 | American Diabetes Association. (2025). Standards of Care in Diabetes—2025. *Diabetes Care*, 48(Suppl 1). | ADA 2025 | Ch2 糖尿病診斷標準 |
| 3 | National Cholesterol Education Program. (2002). ATP III Final Report. *Circulation*, 106(25), 3143-3421. | ATP III | Ch2 血脂異常診斷標準 |

### 資料集來源

| # | 引用 | 用於 |
|---|------|------|
| 4 | Luo, Y., Wu, Q., Meng, R., et al. (2024). Associations of serum uric acid with cardiovascular disease risk factors: a retrospective cohort study in southeastern China. *BMJ Open*, 13(9), e073930. https://doi.org/10.1136/bmjopen-2023-073930 | Ch2 Ch3 資料集原始論文 |
| 5 | Luo, Y., Wu, Q., Meng, R., et al. (2023). Associations of serum uric acid with cardiovascular disease risk factors [Dataset]. *Dryad Digital Repository*. https://doi.org/10.5061/dryad.z08kprrk1 | Ch3 資料集下載來源 |

### 疾病預測研究（Ch2 2.1）

| # | 引用 | 用於 |
|---|------|------|
| 6 | Sun, D., et al. (2017). Recent development of risk-prediction models for incident hypertension: An updated systematic review. *PLoS ONE*, 12(10), e0187240. | Ch2 2.1.1, 2.3 |
| 7 | Kanegae, H., et al. (2020). Highly precise risk prediction model for new-onset hypertension using artificial intelligence techniques. *The Journal of Clinical Hypertension*, 22(3), 453-461. | Ch2 2.1.1, 2.2.2 |
| 8 | Ye, C., et al. (2018). Prediction of Incident Hypertension Within the Next Year: Prospective Study Using Statewide EHR and ML. *JMIR*, 20(1), e22. | Ch2 2.1.1 |
| 9 | Wang, C.-C., Chu, T.-W., & Jang, J.-S. R. (2024). Next-visit prediction and prevention of hypertension using large-scale routine health checkup data. *PLoS ONE*, 19(11), e0313658. | Ch2 2.1.1 |
| 10 | Liu, Y.-Q., et al. (2024). Use of machine learning to predict the incidence of type 2 diabetes among relatively healthy adults. *Diagnostics*, 15(1), 72. | Ch2 2.1.2, 2.4.1 |
| 11 | Yang, C.-C., et al. (2025). Dual machine learning framework for predicting long-term glycemic change and prediabetes risk in young Taiwanese men. *Diagnostics*, 15(19), 2507. | Ch2 2.1.2, 2.2.2, 2.4.1, 2.4.2 |
| 12 | Alaa, A. M., et al. (2019). Cardiovascular disease risk prediction using automated machine learning. *PLoS ONE*, 14(5), e0213653. | Ch2 2.4.1, 表 2-1 |
| 13 | Dinh, A., et al. (2019). A data-driven approach to predicting diabetes and cardiovascular disease with machine learning. *BMC Medical Informatics and Decision Making*, 19(1), 211. | Ch2 2.4.1, 表 2-1 |

### 方法論（Ch2 2.3-2.4）

| # | 引用 | 用於 |
|---|------|------|
| 14 | Fisher, R. A. (1936). The use of multiple measurements in taxonomic problems. *Annals of Eugenics*, 7(2), 179-188. | Ch2 2.3.3 LDA |
| 15 | Hung, M.-H., et al. (2021). Prediction of masked hypertension and masked uncontrolled hypertension using machine learning. *Frontiers in Cardiovascular Medicine*, 8, 778306. | Ch2 2.4.2 SVM |
| 16 | Tsai, H., et al. (2025). Multitask learning multimodal network for chronic disease prediction. *Scientific Reports*, 15(1), 15468. https://doi.org/10.1038/s41598-025-99554-z | Ch2 2.4.3 神經網路 |

### 類別不平衡與評估指標（Ch2 2.5, Ch3 3.5）

| # | 引用 | 用於 |
|---|------|------|
| 17 | He, H., & Garcia, E. A. (2009). Learning from imbalanced data. *IEEE Transactions on Knowledge and Data Engineering*, 21(9), 1263-1284. | Ch2 2.5 |
| 18 | Chawla, N. V., et al. (2002). SMOTE: Synthetic Minority Over-sampling Technique. *JAIR*, 16, 321-357. | Ch2 2.5.1 |
| 19 | Saito, T., & Rehmsmeier, M. (2015). The Precision-Recall Plot Is More Informative than the ROC Plot When Evaluating Binary Classifiers on Imbalanced Datasets. *PLoS ONE*, 10(3), e0118432. | Ch3 3.5.2 PR-AUC 未採用說明 |

### 第一章引用 — 公共衛生與流行病學

| # | 引用 | 用於 |
|---|------|------|
| 20 | World Heart Federation. (2023). *World Heart Report 2023: Confronting the World's Number One Killer*. WHF. | Ch1 [^1] 心血管死亡統計 |
| 21 | 國民健康署（2022）。2017-2020 國民營養健康狀況變遷調查。衛生福利部。 | Ch1 [^2] 台灣三高盛行率 |
| 22 | 國民健康署（2025）。成人預防保健服務擴大至 30 歲公告。衛生福利部。 | Ch1 [^3] 健檢年齡下修 |
| 23 | World Health Organization. (2023). *Global report on hypertension: the race against a silent killer*. WHO. | Ch1 [^4] 全球高血壓報告 |
| 24 | Ohira, T., & Iso, H. (2013). Cardiovascular disease epidemiology in Asia. *Circulation Journal*, 77(7), 1646-1652. | Ch1 [^5] 亞洲心血管流行病學 |
| 25 | Zhao, D. (2021). Epidemiological Features of Cardiovascular Disease in Asia. *JACC: Asia*, 1(1), 1-13. https://doi.org/10.1016/j.jacasi.2021.04.007 | Ch1 [^5] 亞洲心血管流行病學 |
| 26 | Sun, Z., & Zheng, Y. (2025). Metabolic diseases in the East Asian populations. *Nature Reviews Gastroenterology & Hepatology*, 22(7), 500-516. | Ch1 [^6] 東亞代謝疾病 |

### 第一章引用 — 代謝症候群

| # | 引用 | 用於 |
|---|------|------|
| 27 | ~~Jacobs~~ 已移除（DOI 404、PubMed 查無此文，無法核實） | — |
| 28 | Stanciu, S., et al. (2023). Links between metabolic syndrome and hypertension: The relationship with the current antidiabetic drugs. *Metabolites*, 13(1), 87. | Ch1 [^7] 三高共病 |
| 29 | Alberti, K. G., et al. (2009). Harmonizing the metabolic syndrome: A joint interim statement. *Circulation*, 120(16), 1640-1645. | Ch1 [^8] 代謝症候群定義 |

### 第五章引用 — 結論與未來研究

| # | 引用 | 用於 |
|---|------|------|
| 30 | U.S. Department of Agriculture and U.S. Department of Health and Human Services. (2025). *Dietary Guidelines for Americans, 2025-2030* (10th ed.). USDA/HHS. | Ch5 5.2 飲食與三高關聯、5.3 未來研究方向 |
| 31 | Majcherek, D., Ciesielski, A., & Sobczak, P. (2025). AI-driven analysis of diabetes risk determinants in U.S. adults. *PLoS ONE*, 20(9), e0328655. | Ch2 2.3 傳統統計方法比較、Meeting 20 論文報告 |

---

## 已確認事項

| 項目 | 狀態 |
|------|------|
| #4 Luo vs Zhu 作者名確認 → 已確認第一作者為 Luo（BMJ Open 原文核實） | ✅ 完成 |
| #16 Taiwan MTL → 已更新為 Tsai, H., et al. (2025) Scientific Reports | ✅ 完成 |
| #25 JACC: Asia → 作者修正為 Zhao, D.（非 Kario），頁碼 1-13 已確認 | ✅ 完成 |
| #18 Chawla et al. (2002) SMOTE — 格式已確認 ✅ | ✅ 完成 |
| #9 Wang 作者/DOI 修正 → Wang, C.-C., e0313658 | ✅ 完成 |
| #10 Liu 作者/標題修正 → Liu, Y.-Q., "Use of ML..." | ✅ 完成 |
| #11 Chen → Yang, C.-C. et al. (2025)，正文 Ch1/Ch2/Ch5 已全部替換 | ✅ 完成 |
| #12 Alaa 期刊修正 → PLoS ONE 14(5):e0213653（非 Nature Medicine） | ✅ 完成 |
| #15 Hung 作者修正 → Hung, M.-H. 等 10 人 | ✅ 完成 |
| #16 Tsai 文章號修正 → 15468（非 18088） | ✅ 完成 |
| #26 Kim → Sun, Z. & Zheng, Y. / Nat Rev Gastroenterol Hepatol，Ch1 [^6] 已更新 | ✅ 完成 |
| #28 Patti → Stanciu, S. et al. (2023) Metabolites 13(1):87，Ch1 [^7] 已更新 | ✅ 完成 |
| #29 Alberti 縮寫修正 → K. G. M. M. | ✅ 完成 |
| #31 Majcherek DOI/標題/作者修正 → e0328655, 20(9), 3 人 | ✅ 完成 |

---

## 引用統計

| 章節 | 引用數 | 對應編號 |
|------|--------|----------|
| Ch1 | 9 篇 | #20-26, #28-29（#27 已移除） |
| Ch2 | 17 篇 | #1-16, #31 |
| Ch3 | 1 篇 | #19（另引用 Ch2 文獻） |
| Ch4 | 0 篇 | （引用 Ch2/Ch3 文獻） |
| Ch5 | 2 篇 | #30-31（另引用 Ch2 文獻） |
| **合計** | **30 篇**（去重後） | |
